<?xml version="1.0" encoding="UTF-8"?>
<p id="p0270">The results of laboratory findings of COVID-19 patients in China showed an increase in plasma inflammatory cytokine levels, especially interleukin (IL) 6.
 <xref rid="bib23" ref-type="bibr">
  <sup>23</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib38" ref-type="bibr">
  <sup>38</sup>
 </xref> Therefore, the anti-IL6 monoclonal antibody tocilizumab was considered as a potential drug for some COVID-19 cases with extensive lung lesions and elevated IL-6 levels.
 <xref rid="bib20" ref-type="bibr">
  <sup>20</sup>
 </xref> Three clinical trials have been initiated and registered in the Chinese Clinical Trial Registry (
 <ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/index.aspx" id="intref0010" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.chictr.org.cn/index.aspx</ext-link>), but no results or data have been released at this time.
</p>
